Ajay Samkaria: Prevention of Alloimmunization in Females of Childbearing Age
Ajay Samkaria, Product and Application Manager at Diagast Transfusion Medicine, shared a post on LinkedIn:
“In transfusion medicine, prevention is always better than reaction.
One of the most critical yet often under-emphasized practices is extended phenotyping – especially for Rh (C, c, E, e) and Kell antigens in females.
Why does this matter?
Because alloimmunization doesn’t just affect a single transfusion – it can impact future pregnancies and neonatal outcomes.
A young female patient exposed to mismatched Rh or Kell antigens today may develop clinically significant antibodies tomorrow.
These antibodies can lead to Hemolytic Disease of the Fetus and Newborn (HDFN), posing serious risks to both mother and baby.
By proactively providing Rh and Kell matched blood for females of childbearing age, we are not just ensuring safe transfusion – we are protecting future lives.
This is not just good practice.
It is responsible transfusion medicine.
Let’s move from compatibility to foresight.”
Stay updated with Hemostasis Today.
-
Aug 11, 2026, 07:50When Access to Care Changes Everything – WFH
-
Aug 11, 2026, 07:41Kevin Land: How Cellular Therapy Is Changing Transfusion Medicine
-
Aug 11, 2026, 07:35Kuldeep Singh Bhadauria: Building the Future of Hemophilia Care in India
-
Aug 11, 2026, 07:28Archil Jaliashvili: When Every Minute Matters Time Becomes a Therapy
-
Aug 11, 2026, 07:05Mavis Agnes Kisakye: Building Sustainable Transition Pathways in Hemophilia Care
-
Aug 11, 2026, 06:48Rishdha Roshad: What Happens to the Brain During Cardiopulmonary Bypass?
-
Aug 11, 2026, 05:53Isaac Okello: Strengthening Sickle Cell Advocacy in Uganda
-
Aug 11, 2026, 05:38Rami Unterman: A Simple New Biomarker for Fibrotic ILDs
-
Aug 11, 2026, 04:10Haroun Gajraj: CLaCS vs Sclerotherapy – What Does the Evidence Show